J Gynecol Oncol.  2024 Jan;35(1):e30. 10.3802/jgo.2024.35.e30.

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

• García E
• Ayoub N
• Tewari KS

• KMID: 2564861
• DOI: http://doi.org/10.3802/jgo.2024.35.e30

Abstract

Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.

Keyword

Cervical Cancer; Chemoradiation; Immune Checkpoint Inhibitor; Antibody Drug Conjugate; Immunotherapy